Results 11 to 20 of about 12,296,614 (200)
Liposomal amphotericin B-the present. [PDF]
J Antimicrob Chemother, 2022 AbstractMost invasive fungal infections are opportunistic in nature but the epidemiology is constantly changing, with new risk groups being identified. Neutropenia is a classical risk factor for fungal infections, while critically ill patients in the ICU are now increasingly at risk of yeast and mould infections.
Maertens J +3 more
europepmc +6 more sources
Liposomal amphotericin B and leishmaniasis: Dose and response
Journal of Global Infectious Diseases, 2010 Liposomal amphotericin B has been used with increasing frequency to treat visceral leishmaniasis (VL). It is the treatment of choice for immunocompetent patients in the Mediterranean region and the preferred drug for HIV/VL co-infection.
Shyam Sundar, Jaya Chakravarty
doaj +4 more sources
Methods for particle size reduction of liposomal amphotericin B
Vietnam Journal of Science, Technology and Engineering, 2018 Liposomal amphotericin B were prepared by thin film hydration technique. Particle size was reduced by ultrasonic device and high pressure homogeneous device.
Tuan Quang Nguyen +3 more
doaj +2 more sources
Research and Reports in Tropical Medicine, 2019 Mohammad Reza Shirzadi1,21Center for Communicable Diseases Control, Ministry of Health and Medical Education, Tehran, Iran; 2Center for Research of Endemic Parasites of Iran (CREPI), Tehran University of Medical Science, Tehran, IranAbstract: The genus ...
Shirzadi MR
doaj +1 more source
Liposomal amphotericin B-the past. [PDF]
J Antimicrob Chemother, 2022 Abstract The discovery of amphotericin B, a polyene antifungal compound, in the 1950s, and the formulation of this compound in a liposomal drug delivery system, has resulted in decades of use in systemic fungal infections. The use of liposomal amphotericin B formulation is referenced in many international guidelines for the treatment of ...
Brüggemann RJ +2 more
europepmc +5 more sources
Liposomal amphotericin B-the future. [PDF]
J Antimicrob Chemother, 2022 AbstractAdvances in medicine have led to a growing number of people with compromised or suppressed immune systems who are susceptible to invasive fungal infections. In particular, severe fungal infections are becoming increasingly common in ICUs, affecting people within and outside of traditional risk groups alike.
Hoenigl M +4 more
europepmc +8 more sources
Clinical Medicine Insights: Case Reports, 2014 Amphotericin-B, a broad spectrum antifungal agent, has been known to cause adverse effects such as nephrotoxicity and infusion-related side effects such as fever, chills, rigor, and arthralgias. However, ototoxicity as an adverse effect of Amphotericin-B
PC Das +3 more
doaj +2 more sources
Journal of Fungi, 2020 Disseminated histoplasmosis is the main AIDS-defining infection of French Guiana. We aim to describe our therapeutic experience for 349 patients with disseminated histoplasmosis between 1 January 1981 and 10 January 2014 in French Guiana.
Mathieu Nacher +11 more
doaj +1 more source
Journal of Medical Case Reports, 2022 Background Invasive pulmonary Aspergillus and invasive bronchial aspergillosis is a life-threatening opportunistic fungal infection that predominantly affects immunocompromised hosts.
Shuku Sato +7 more
doaj +1 more source
Persistent dyselectrolytemia in a neonate induced by liposomal amphotericin B. A case report
Frontiers in Pediatrics, 2023 BackgroundNephrotoxicity is the most frequent serious adverse effect associated with amphotericin B deoxycholate treatment, for this reason, in recent years it has been relegated from routine clinical practice and replaced by the new liposomal ...
Adrian Puertas Sanjuan +4 more
doaj +1 more source